BACKGROUND: In this study, positron emission tomography-computed tomography (PET-CT) was used to monitor the maximal standard uptake value (SUVmax) in @entity2220 @entity1 with @entity470 ( @entity470 ) mutation to prove its role in predicting the prognosis of targeted therapy. METHODS: A total of 46 @entity1 with @entity2220 (IIIb-IV stage) were enrolled in the current study. They were positive for @entity470 mutation. All @entity1 received @entity4562 (250   mg per day, administered orally). PET-CT was conducted prior to (at baseline) and six months after @entity4562 administration for the lesion size and SUVmax. The recommendations of the European Organization for Research and Treatment of @entity5 criteria were chosen for PET assessment. Metabolic response (SUV decline < -25%) was compared with morphologic response evaluated by CT scan and overall survival. RESULT: Compared to @entity1 with    SUV% >=  25% (progressive @entity209 ), the survival time was significantly prolonged in    SUV% < -25% (including complete metabolic response and progressive @entity209 ) (10.6/18.4, P = 0.000), but was not in -25%  <=    SUV% < 25% (stable @entity209 ) (10.6/10.7, P = 0.088). @entity1 who achieved    SUV% < -25% after treatment were associated with a longer median survival, higher control rate, and better prognosis. There was a strong correlation between SUV changes (   SUV%) and CT size change (   lesion size%) (R(2) = 0.891, P = 0.000). CONCLUSION: Changes in the SUV could be used to predict the prognosis of targeted therapy in @entity2220 .

Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epithermal growth factor receptor'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disease'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['advanced lung adenocarcinoma']
@entity2220 :: (MESH:C538231,Disease) :: ['lung adenocarcinoma']
